» Articles » PMID: 6842217

Speech Therapy for Parkinson's Disease

Overview
Date 1983 Feb 1
PMID 6842217
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty-six patients with the speech disorder of Parkinson's disease received daily speech therapy (prosodic exercises) at home for 2 to 3 weeks. There were significant improvements in speech as assessed by scores for prosodic abnormality and intelligibility' and these were maintained in part for up to 3 months. The degree of improvement was clinically and psychologically important, and relatives commented on the social benefits. The use of a visual reinforcement device produced limited benefit over and above that from prosodic exercises alone, except to patients with severe speech disorder.

Citing Articles

The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT.

Sackley C, Rick C, Brady M, Burton C, Jowett S, Patel S Health Technol Assess. 2024; 28(58):1-141.

PMID: 39364774 PMC: 11474952. DOI: 10.3310/ADWP8001.


Prosodic characteristics of prepausal words produced by patients with neurodegenerative disease.

Cho S, Agmon G, Shellikeri S, Cousins K, Ash S, Irwin D Speech Prosody. 2022; 2022:120-124.

PMID: 36444200 PMC: 9701527. DOI: 10.21437/speechprosody.2022-25.


A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised....

Sackley C, Rick C, Au P, Brady M, Beaton G, Burton C Trials. 2020; 21(1):436.

PMID: 32460885 PMC: 7251680. DOI: 10.1186/s13063-020-04354-7.


Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot).

Sackley C, Smith C, Rick C, Brady M, Ives N, Patel S Pilot Feasibility Stud. 2018; 4:30.

PMID: 29344405 PMC: 5763537. DOI: 10.1186/s40814-017-0222-z.


Utilization of rehabilitation therapy services in Parkinson disease in the United States.

Fullard M, Thibault D, Hill A, Fox J, Bhatti D, Burack M Neurology. 2017; 89(11):1162-1169.

PMID: 28835397 PMC: 5595277. DOI: 10.1212/WNL.0000000000004355.


References
1.
Sarno M . Speech impairment in Parkinson's disease. Arch Phys Med Rehabil. 1968; 49(5):269-75. View

2.
RIGRODSKY S, MORRISON E . Speech changes in parkinsonism during L-dopa therapy: preliminary findings. J Am Geriatr Soc. 1970; 18(2):142-51. DOI: 10.1111/j.1532-5415.1970.tb02111.x. View

3.
LEANDERSON R, Meyerson B, Persson A . Effect of L-dopa on speech in Parkinsonism. An EMG study of labial articulatory function. J Neurol Neurosurg Psychiatry. 1971; 34(6):679-81. PMC: 1083501. DOI: 10.1136/jnnp.34.6.679. View

4.
MONRAD-KROHN G . [Some remarks on prosodic alterations and their consequences in the neurological clinic]. Acta Psychiatr Neurol Scand Suppl. 1956; 108:265-7. View

5.
Uziel A, Bohe M, CADILHAC J, PASSOUANT P . [Voice and speech disorders in the Parkinsonian syndrome]. Folia Phoniatr (Basel). 1975; 27(3):166-76. View